Barbara Guest's Contact Details

Barbara Guest's Company Details

LineaGen Research Corporation

Millcreek, UT, US • 100 - 249 Employees
Hospital/Clinic

Lineagen is a provider of advanced genetic diagnostics for children with neurodevelopmental disorders. Our solutions incorporate proprietary technology for the highest clinical detection rate and the most informative variant interpretations.FirstStepDx PLUS, an advanced whole-genome chromosomal microarray (CMA), may be ordered with fragile X syndrome testing to help diagnose or rule out hundreds of genetic conditions associated with developmental delay (DD), intellectual disability (ID), or autism spectrum disorder (ASD).What is unique about FirstStepDx PLUS?• Optimized to have the highest detection rate of any commercially available CMA test• Has the most clinically relevant detection sites, with 88k+ additional probes exclusively available through Lineagen, to identify genetic variants clinically associated with ASD/DD. This results in a two-fold increase in clinical detection for genetic variants that underlie ASD.• Comprehensive insurance support and expert reimbursement processes• Superior patient testing experience by incorporating genetic counseling• Stress-free and more clinically informative non-invasive cheek swab for DNA collectionNextStepDx PLUS is characteristic of Lineagen's approach, as it homes in on genetic areas of clinical relevance for NDD specialists and renders complex genetic data into readily useable form appropriate for all providers in the patient's continuum of care. NextStepDx PLUS specializes in extracting the clinical value of exome technology and eliminates the risk of providers misinterpreting genetic information.For patients showing signs of regression, the clinical detection rate with NextStepDx PLUS may be further increased with the option of including mitochondrial DNA testing.As part of our patient services support, Lineagen provides free online M-CHAT-R account for your practice - visit M-CHAT.org today!The "Modified Checklist for Autism in Toddlers, Revised" is a recommended tool for developmental screening at both the 18 and 24 month well-child visits. This quick and accurate online autism risk assessment can be done in office or at home, and gives you a place to review, print and save the results.